Scott Edwards

Scott Edwards

Company: OcuTerra Therapeutics

Job title: Chief Development Operating Officer


Development of OTT166 an RGD-Binding Integrin Antagonist for the Topical Treatment of Diabetic Retinopathy 4:10 pm

Distributes to posterior segment of the eye after eye drop administration Reduces neovascularization and vessel leakage in multiple animal models of diabetic retinopathy and wet-AMD Phase 1 clinical data show safety and tolerability and evidence of biological activity – proceeding to Phase 2Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.